Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2

2(40.0%)

Phase 3

2(40.0%)

N/A

1(20.0%)

5Total

Phase 2(2)

Phase 3(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT07175584Not ApplicableNot Yet Recruiting

A Clinical Study on Alleviating Hemorrhoids-related Symptoms of Pelvic Radiation Therapy

Role: collaborator

NCT06086457Phase 3Recruiting

PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer

Role: collaborator

NCT04192682Phase 2Unknown

Anlotinib Combined With Sintilimab as Second-line Treatment or Beyond in Patients With Small Cell Lung Cancer

Role: lead

NCT03129256Phase 2Completed

An Exploration of Apatinib Combined With S-1 in Patients With Advanced Non-small Cell Lung Cancer

Role: lead

NCT02485548Phase 3Unknown

Cisplatin Plus Raltitrexed or 5-fluorouracil Concurrent With Radiotherapy for Head and Neck Squamous Cell Cancer

Role: collaborator

All 5 trials loaded